title: A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer.
abstract: BACKGROUND
  This phase II study evaluated the feasibility and efficacy of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer (MBC).
  
  
  METHODS
  Women with MBC requiring first-line chemotherapy for progressive disease (n = 106) were randomized and received 3-weekly monotherapy with docetaxel (T, 100 mg/m2, 1-h i.v. infusion) and doxorubicin (A, 75 mg/m2, 20-30-min i.v. infusion) either on a cycle-by-cycle alternating basis (ATATATAT, n = 51) or sequentially each for four cycles (TTTTAAAA, n = 55).
  
  
  RESULTS
  For both regimens, the median number of cycles administered was the maximum of eight. The alternating and sequential groups achieved similar objective tumor response rates (60% and 67%, respectively) and similar median duration of response (47 and 44 weeks, respectively). With a median follow-up of 31 months, median survival times were estimated at 20 and 26 months in the alternating and sequential groups, respectively. No unexpected toxicities were reported. Compared with alternating therapy, patients receiving sequential therapy were more likely to complete the planned eight chemotherapy cycles (69% versus 63%), and had a lower incidence of febrile neutropenia (2% versus 14%).
  
  
  CONCLUSIONS
  Alternating and sequential docetaxel-doxorubicin regimens are viable alternatives to simultaneous combination therapy in MBC, with sequential therapy achieving slightly higher response rates and improved tolerability compared with alternating therapy.
authors.affiliation: University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium. robert.paridaens@uz.kuleuven.ac.be
authors.forename: R
authors.initials: R
authors.lastname: Paridaens
authors.forename: F
authors.initials: F
authors.lastname: Van Aelst
authors.forename: V
authors.initials: V
authors.lastname: Georgoulias
authors.forename: H
authors.initials: H
authors.lastname: Samonnig
authors.forename: V
authors.initials: V
authors.lastname: Cocquyt
authors.forename: C
authors.initials: C
authors.lastname: Zielinski
authors.forename: H
authors.initials: H
authors.lastname: Hausmaninger
authors.forename: P
authors.initials: P
authors.lastname: Willemse
authors.forename: Y
authors.initials: Y
authors.lastname: Boudraa
authors.forename: J
authors.initials: J
authors.lastname: Wildiers
authors.forename: C
authors.initials: C
authors.lastname: Ramazeilles
authors.forename: N
authors.initials: N
authors.lastname: Azli
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000077143:Docetaxel; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009503:Neutropenia / Q000139:chemically induced; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D004317:Doxorubicin